Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Subscribe To Our Newsletter & Stay Updated